Meet Adoram Therapeutics in Kyoto next week at the STS Forum, a 'platform for collaborative networks among global leaders in academia, industry and government, to build a better world together'. Co-CEO David Pejoski will be presenting at the Breakthrough Swiss Deeptech Session: https://lnkd.in/eW3SY9yW https://lnkd.in/eumeVs5w
Adoram Therapeutics
Biotechnologieforschung
Grand Lancy, Grand Lancy 1.043 Follower:innen
Leveraging allosteric biochemistry to address unmet medical needs
Info
Adoram Therapeutics is developing a suite of therapies with an allosteric molecular mode of action, which can either positively or negatively modulate the signaling of specific GPCRs - the largest class of human receptors. Our foremost asset is a small molecule immunotherapy to treat patients with solid tumors. Thanks to its unique allosteric mode of action, this 3rd generation adenosine 2A receptor antagonist retains its potency in high adenosine (immunosuppressive) microenvironments, such as those found in many solid tumors, and is therefore intended to be used as a treatment for a wide range of cancers.
- Website
-
https://adoram.ch/
Externer Link zu Adoram Therapeutics
- Branche
- Biotechnologieforschung
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Grand Lancy, Grand Lancy
- Art
- Privatunternehmen
- Gegründet
- 2022
Orte
-
Primär
Wegbeschreibung
Grand Lancy, Grand Lancy 1212, CH
Beschäftigte von Adoram Therapeutics
Updates
-
Exciting times at Adoram Therapeutics SA, our development pipeline is expanding with new promising targets/indincations. Vote to rank Adoram among the top 100 startups in Switzerland. You can vote by pressing the "vote now" icon in the link below https://lnkd.in/eSjDZ-ts
Great news - Adoram Therapeutics is nominated as a Top 100 #Swiss #Startup! Our discovery campaigns for novel anti-#inflammation and anti-#cancer therapies are progressing nicely. There is a voting link at the top of this page https://lnkd.in/eGBQSnh2, which only takes a few clicks. We thank you for your support - it means the world to us!
Adoram Therapeutics SA
startup.ch
-
Great news - Adoram Therapeutics is nominated as a Top 100 #Swiss #Startup! Our discovery campaigns for novel anti-#inflammation and anti-#cancer therapies are progressing nicely. There is a voting link at the top of this page https://lnkd.in/eGBQSnh2, which only takes a few clicks. We thank you for your support - it means the world to us!
Adoram Therapeutics SA
startup.ch
-
Many thanks to Venturelab for the chance to be a part of the National Venture Leaders team. We're heading to Boston soon where Swissnex will be hosting the 10 Swiss-based biotech entrepreneurs. You can learn a little more about the Venture Leaders roadshow and Adoram Therapeutics in this interview: https://lnkd.in/e5T28t3X #startups #biotech #cancer #inflammation
Adoram Therapeutics: The Venture Leaders Biotech creating new treatments for patients with solid tumors or immune-based diseases
venturelab.swiss
-
Join us at the Swiss Biotech day in Basel, today at 17h45, for a kick-off pitch from each of the Venture Leaders Biotech 2024 cohort...including Adoram Therapeutics #VleadersBiotech Venturelab
Kick-off day with the Venture Leaders Biotech 2024 at the Swiss Biotech days: if you are on site, join us at 17h45 in room Singapore for the pitchfest to meet the new team! And looking forward to be in Boston from May 13th to 16th, #Boston investors and friends, reach out to make sure we meet! Venture Leaders Biotech is organized by Venturelab in partnership with Swissnex in Boston and New York and supported by Debiopharm , EPFL , ETH Zürich, , Hansjörg Wyss, Kellerhals Carrard Startup & VC Desk, Novartis, Swiss Biotech Association and VISCHER. https://lnkd.in/emVRyu87 #VLeadersBiotech #swissbiotechday
Venture Leaders Biotech 2024: 10 innovative startups selected for the Boston roadshow
venturelab.swiss
-
Adoram Therapeutics, a University of Geneva spin-off, is developing next-generation (allosteric) small molecule drugs, which are safer and more effective than conventional (orthosteric) small molecules. We have developed an allosteric screening platform to efficiently identify positive or negative modulators of GPCR drug targets. We are securing investments to progress two preclinical stage assets towards human trials, and to expand our pipeline. Meet Adoram Therapeutics @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW
-
-
Adoram Therapeutics is presenting a data update on our #immunotherapy drug development program at the ESMO - European Society for Medical Oncology Annual Immuno-Oncology Congress #ESMOImmuno23 in Geneva this week. David Pejoski will be there in person on Thursday 7th December to present abstract P146. Looking forward to seeing you there!
Ähnliche Seiten
Finanzierung
Adoram Therapeutics
Insgesamt 1 Finanzierungsrunde
![]()
FONGIT Innovation Fund
Weitere Informationen auf Crunchbase
Letzte Runde
Fremdfinanzierung
Externer Crunchbase-Link für die letzte Finanzierungsrunde
115.516,00 $
Investor:innen